Background: Both genetic and environmental factors contribute to Parkinson's disease (PD) risk.
Objective: We investigated the potential association of several relevant variables with PD age at onset (AAO), focusing on LRRK2 p.G2019S and GBA p.N370S mutations.
Methods: Ashkenazi Jewish (AJ) PD patients, screened for LRRK2 and GBA mutations, underwent an interview regarding exposure to the following environmental and lifestyle factors: cigarette smoking, consumption of coffee, tea and alcohol, history of head injury and rural living. Multivariate linear regression (adjusted for sex) was used to examine the association with AAO, and models included LRRK2 and GBA mutation status (carrier/non-carriers), single environmental variable and their interactions terms, as independent variables.
Results: 225 Israeli AJ PD patients were enrolled: 65 LRRK2 p.G2019S mutation carriers, 60 GBA p.N370S carriers and 100 non-carries of both mutations. In the dichotomized exposure/non-exposure analyses, positive LRRK2 p.G2019S status was associated with younger AAO in all models, at nominal or near significant levels (p = 0.033-0.082). Cigarette smoking was associated with older AAO (p = 0.032), and the interaction between GBA p.N370S and history of head injury was associated with younger AAO (p = 0.049), both at nominal significance. There was no indication of a consistent main effect for GBA p.N370S status or significant LRRK2 p.G2019S-environmental factor interaction. In the dose-dependent analysis, increased coffee and tea consumption levels were associated with older AAO (p = 0.001 and p = 0.002, respectively).
Conclusions: Our results suggest that both genetic and environmental factors may affect AAO in PD patients, but validation in additional samples is required.
Keywords: GBA p.N370S; LRRK2 p.G2019S; Parkinson’s disease; age at onset; caffeine; environmental factors; gene-environment interaction; head injury; lifestyle habits; smoking; tea.
Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?Mol Genet Metab. 2019 Dec;128(4):470-475. doi: 10.1016/j.ymgme.2019.10.001. Epub 2019 Oct 13. Mol Genet Metab. 2019. PMID: 31662221
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.Brain. 2015 Sep;138(Pt 9):2648-58. doi: 10.1093/brain/awv179. Epub 2015 Jun 27. Brain. 2015. PMID: 26117366 Free PMC article.
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset.Neurology. 2008 Jun 10;70(24):2277-83. doi: 10.1212/01.wnl.0000304039.11891.29. Epub 2008 Apr 23. Neurology. 2008. PMID: 18434642
The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.J Neural Transm (Vienna). 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. J Neural Transm (Vienna). 2009. PMID: 19756366 Review.
Non-cell autonomous mechanism of Parkinson's disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis.Brain Res. 2019 Nov 1;1722:146342. doi: 10.1016/j.brainres.2019.146342. Epub 2019 Jul 19. Brain Res. 2019. PMID: 31330122 Review.